(redirected from Invasive candidiasis)
Also found in: Medical.


n. fungemia, presencia de hongos en la sangre.
References in periodicals archive ?
Anidulafungin and caspofungin have been approved for treatment of candidaemia and invasive candidiasis by US Food and Drug Administration (FDA).
Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE).
"Rezafungin achieved positive topline results in its Phase 2 STRIVE B trial, which adds to the growing body of evidence supporting the efficacy and safety of this once-weekly treatment for candidemia and invasive candidiasis, and we continue to enroll patients in our Phase 3 ReSTORE trial.
As such Scynexis can apply for a Fast Track designation for the treatment of invasive candidiasis (including candida auris), invasive aspergillosis, and vulvovaginal candidiasis.
Epidemiology of invasive candidiasis: a persistent public health problem.
New diagnostic tests may improve diagnostic performance, particularly in invasive candidiasis cases (50, 51).
Studying the prevalence, species distribution, and detection of in vitro production of phospholipase from Candida isolated from cases of invasive candidiasis. J.
Invasive candidiasis is a life-threatening infection caused by various Candida species.
The management of serious and life-threatening invasive candidiasis remains severely hampered by delays in diagnosis and the lack of reliable diagnostic methods that allow detection of both fungemia and tissue invasion by Candida species.
Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies.
Clinical applications for echinocandins include candidiasis in patients with neutropenia, invasive candidiasis, candidiasis in severely ill patients, and neutropenic refractory esophageal candidiasis.
Fungal empyema thoracis is a rare but severe form of invasive candidiasis with high mortality.
Full browser ?